Celldex Therapeutics, Inc.
Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
CLDX | NDAQ
Overview
Corporate Details
- ISIN(s):
- US15117B2025
- LEI:
- Country:
- United States of America
- Address:
- 53 FRONTAGE ROAD, 8827 HAMPTON
- Website:
- https://celldex.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering new approaches in immunology to develop life-changing, antibody-based therapies. The company leverages its deep expertise and proprietary technologies to discover and develop treatments targeting core pathological drivers of disease. Its lead program, barzolvolimab, is a humanized monoclonal antibody that inhibits KIT, a key receptor for the function and survival of mast cells. This therapeutic candidate is being developed for severe inflammatory, allergic, and autoimmune diseases, aiming to provide a best-in-class treatment option for patients with conditions driven by mast cell activity.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Celldex Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Celldex Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Celldex Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
